Table 1.
Comparison of clinical features and patient outcomes stratified by EIA and Illumigene test resulta
| Clinical characteristic | No. (%) with indicated Illumigene C. difficile LAMP assay result |
|||
|---|---|---|---|---|
| EIA toxin positive (n = 16) |
EIA toxin negative (n = 82) |
|||
| Pos (n = 15) | Neg (n = 1) | Pos (n = 15) | Neg (n = 67) | |
| Diarrheab | 15 (100) | 1 (100) | 10 (67) | 51 (76) |
| Non-CDI antibiotic treatment ceased | 13/14 (93) | 1 (100) | 9/12 (75) | 27/52 (52) |
| CDI antibiotic treatment | 13 (87) | 1 (100) | 5 (33) | 8 (12) |
| Symptom improvement | ||||
| Day 3 | 11 (73) | 0 (0) | 13 (87) | 54 (81) |
| Day 7 | 12 (80) | 0 (0) | 14 (93) | 61 (91) |
| Outcomes | ||||
| Relapsec | 1 (7) | 0 (0) | 2 (13)d | 0 (0) |
| Mortality by day 30e | 2 (13) | 0 (0) | 1 (7) | 6 (9) |
a
CDI, C. difficile infection; Pos, positive; Neg, negative.
b
Αt least 3 loose stools in the 24 h prior to sample collection.
c
Within 30 days.
d
Clinical relapse at 2 weeks in 1 nontreated LAMP-positive patient with repeat EIA-negative stool sample results.
e
Death not attributed to CDI in any of the cases.